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Abstract
Background: It has been suggested that the use of adjunctive hyperbaric oxygen therapy improves the healing of
diabetic foot ulcers, and decreases the risk of lower extremity amputations. A limited number of studies have used
a double blind approach to evaluate the efficacy of hyperbaric oxygen therapy in the treatment of diabetic ulcers.
The primary aim of this study is to assess the efficacy of hyperbaric oxygen therapy plus standard wound care
compared with standard wound care alone in preventing the need for major amputation in patients with diabetes
mellitus and chronic ulcers of the lower limb.
Methods/Design: One hundred and eighteen (59 patients per arm) patients with non-healing diabetic ulcers of
the lower limb, referred to the Judy Dan Research and Treatment Centre are being recruited if they are at least 18
years of age, have either Type 1 or 2 diabetes with a Wagner grading of foot lesions 2, 3 or 4 on lower limb not
healing for at least 4 weeks. Patients receive hyperbaric oxygen therapy every day for 6 weeks during the
treatment phase and are provided ongoing wound care and weekly assessments. Patients are required to return to
the study centre every week for an additional 6 weeks of follow-up for wound evaluation and management. The
primary outcome is freedom from having, or meeting the criteria for, a major amputation (below knee amputation,
or metatarsal level) up to 12 weeks after randomization. The decision to amputate is made by a vascular surgeon.
Other outcomes include wound healing, effectiveness, safety, healthcare resource utilization, quality of life, and
cost-effectiveness. The study will run for a total of about 3 years.
Discussion: The results of this study will provide detailed information on the efficacy of hyperbaric oxygen therapy
for the treatment of non-healing ulcers of the lower limb. This will be the first double-blind randomized controlled
trial for this health technology which evaluates the efficacy of hyperbaric oxygen therapy in prevention of
amputations in diabetic patients.
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Non-healing foot ulcers and their sequelae are a major
source of morbidity and resource use for patients with dia-
betes mellitus [1-4]. Peripheral neuropathy, peripheral vas-
cular disease, and poor glycemic control, in conjunction
with minor foot trauma, increase the likelihood that
patients with diabetes will develop foot ulcers. Because of
t h en e u r o p a t h y ,af o o ti n j u r ya n ds u b s e q u e n ti n f e c t i o n
cannot be felt and since circulation is also affected, wound
healing is compromised and causes the original ulcer to
become chronic and may eventually require amputation
[5-7]. For those patients with ulcers, excess healthcare
costs are substantial. Ramsey et al [8] found that the attri-
butable cost for a 40- to 65-year-old male with a new foot
ulcer was $27,987 USD for the 2 years after diagnosis. Not
surprisingly, quality of life is significantly reduced in
patients with ulcers and after major amputations [9].
In patients with diabetes, it is estimated that the
annual incidence of foot ulcers varies from 1.2 to 3.0%
[8,10] and the rate of lower extremity amputation (LEA)
has been measured to range between 6% and 23.5%
[11]. Major LEAs are amputations of the leg above or
below the knee, whereas minor LEAs involve amputa-
tion of the toes or the forefoot [12]. The incidence of
major amputation in a study of 8,905 patients with dia-
betes in the United States was found to be 0.9% [8].
Additionally, a significant proportion of these amputees
undergo further amputations of the same or other limb
[8,11,13,14].
The standard of care for treating diabetic foot ulcers
includes the maintenance of optimal blood glucose levels;
use of debridement, antibacterials, and dressings; admin-
istration of antibiotics to control infection; adequate
nutrition; pressure relief in the areas of the foot that are
most subject to weight bearing; and amputation. There
has also been increasing interest in the use of hyperbaric
oxygen therapy (HBOT) as an adjunctive treatment for
diabetic ulcers. It has been suggested that the use of
adjunctive HBOT will improve the healing of diabetic
lower leg ulcers, and decrease the risk of LEA [15-20].
HBOT is an established technology that has been in
use for more than 40 years. For wound healing treat-
ment, a person is placed in a compression chamber
under pressure greater than one atmosphere absolute
(ATA) of 100% oxygen. The pressure increases the
level of oxygen dissolved in the blood plasma affecting
the immune system, wound healing, and vascular tone
[21]. Treatment regimens vary from 90-120 minutes
once or twice daily for approximately 30 sessions [22].
Complications associated with HBOT are infrequent
but may include claustrophobia; ear, sinus or lung
damage due to the pressure; temporary worsening of
short sightedness, rarely is permanent; and oxygen poi-
soning [23]. Careful monitoring during the treatment
sessions and follow-up by a trained health care provi-
der is recommended.
There is evidence to support that adjunctive HBOT is
more effective in the treatment of chronic diabetic foot
ulcers than standard care alone. However, this evidence
of efficacy for chronic diabetic foot ulcers is limited. In
particular, several, very small, prospective, randomized,
controlled trials can be identified in the published litera-
ture to date [16,17,19]. The first trial [17] randomized 30
patients, the second randomized 68 patients [16]. Only
two double blind placebo controlled trials have ever been
reported including a trial conducted in 2003 which ran-
domized just 16 patients [19], while the more recent lar-
gest trial to date successfully randomized and completed
37 patients in each arm [24]. In this latest study, the pri-
mary outcome was healing of the index wound, however,
the healing rate in the control group in this study was
very low at 29%. All trials demonstrated that more
wounds healed in HBOT-treated patients compared to
the control group. Two of the three studies [16,17]
demonstrated a reduction of major LEA in the HBOT
group, while the other study showed no difference
between the groups. In addition, successes of adjunct
HBOT for the treatment of diabetic foot ulcers have been
reported in a few small case series and retrospective or
prospective cohorts [15,18,25-28]. However, many of
these originated from one clinical centre [16,18,27,28].
Using this limited evidence, several health technology
assessments and systematic literature reviews have been
conducted that suggested that adjunctive HBOT for dia-
betic foot ulcers is more effective than standard care
alone [29-37]. At the same time, all reports recommend
that good quality studies are required to confirm the
comparative benefits of the technology for chronic dia-
betic foot ulcers in order to help clinicians and policy-
makers decide whether HBOT should be more widely
utilized [33,34,37].
Currently in Ontario, HBOT is an accepted treatment
for chronic diabetic ulcers and physicians who provide
this service are reimbursed under the current Ontario
Health Insurance Plan (OHIP) payment schedule. How-
ever there are only a few facilities which provide com-
prehensive wound care and adjunctive HBOT.
A recent review of the HBOT literature concluded that
the quality of the evidence assessing the efficacy of
HBOT as an adjunct to standard therapy for people with
non-healing diabetic foot ulcers is low, and the results
are inconsistent [32]. Thus, the goal of the current study
is to conduct a well-designed, double-blind randomized
controlled trial that would provide quality efficacy data
on the use of adjunctive HBOT for the prevention of
major limb amputations for patients with moderate and
severe chronic diabetic foot ulcers. To better assess the
place of HBOT in modern wound care, the best practice
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applied in both control and treatment arms.
This study was initiated based on a recommendation by
the Ontario Health Technology Advisory Committee that
stated that a “well designed, adequately powered, clinical
trial be undertaken to provide evidence on which to
make a definitive decision on the effectiveness of HBOT
in the treatment of non-healing diabetic foot ulcers”.
Objectives
Primary Objective
This study is intended to assess the efficacy of HBOT
plus standard wound care compared with standard
wound care alone in preventing the need for major
amputation in patients with diabetes (Type 1 or 2) with
moderate to severe chronic wounds of lower limbs
(Wagner scale 2 to 4) [38].
Secondary Objectives
Further objectives of the study are to determine if
HBOT, in combination with standard wound care, sig-
nificantly improves the healing of chronic ulcers com-
pared with standard wound care alone through the
assessment of wound measurements and wound closure.
The safety, amount of health care resource utilization,
health-related quality of life (HRQL), and cost-effective-
ness of HBOT will also be measured.
Hypothesis
HBOT plus standard wound care is more effective than
standard wound care alone at preventing the need for
major amputation (metatarsal and up) in patients with
diabetes with moderate to severe chronic wounds of
lower limbs.
Methods/Design
Design
Patients are randomised either to receive standard
wound care alone or HBOT in combination with stan-
dard wound care for the treatment of chronic lower
limb ulcers in patients with diabetes (Figure 1).
Setting and participants
This study is being conducted at the Judy Dan Wound
Care and Research Centre an University Health Network
Research affiliated wound care facility. Patients with non-
healing diabetic lower limb ulcers are referred by physi-
cians and also identified through a number of wound
care clinics in the Greater Toronto Area (GTA) as well
as from regional Community Care Access Centres.
Inclusion Criteria
1) Age ≥ 18 years; 2) Type 1 or 2 Diabetes Mellitus; and
3) Wagner grading [38] of foot lesions 2,3 or 4 on lower
limb not healing for at least 4 weeks.
Exclusion Criteria
1) Impending urgent amputation due to ongoing or exa-
cerbated infection; 2) exposed calcaneus bone with no
prospect of weight bearing potential even if defect has
been healed; 3) any of the following medical conditions
which preclude safe treatment in a monoplace chamber:
clinical depression; severe dementia; claustrophobia; sei-
zure disorder; active asthma; severe chronic obstructive
pulmonary disease; previous thoracic surgery; previous
spontaneous or trauma induced pneumothorax; history
of severe congestive heart failure with left ventricular
ejection fraction less than 20%; unstable angina; chronic
sinusitis; chronic or acute otitis media or major ear
drum trauma; severe kyphoscoliosis; severe arthritis; or
morbid obesity; 4) history of chemotherapy with use of
Bleomycin; 5) participation in another investigative drug
or device trial currently or within the last 30 days; 6)
current candidates for vascular surgery, angioplasty or
stenting; 7) major large vessel disease; 8) undergone vas-
cular surgery or angioplasty within the last 3 months; 9)
women who are currently pregnant or are breast feeding
or women of childbearing potential who are not cur-
rently taking adequate birth control.
Sample Size
A comprehensive search and review of the electronic
medical literature databases was conducted to identify
randomized controlled trials of HBOT versus standard
treatment to collect data to calculate the sample size
required for the current study. Sample size calculations
were to be based on evidence from published rando-
mized controlled trials comparing the efficacy, in terms
of rates of major amputation, of HBOT versus standard
treatment for patients with various wound classifications
using the Wagner’s Ulcer Classification Grade [38].
Of the 348 citations obtained, only one study [16,19]
reported the rates of major amputation for Wagner’s
classifications necessary for the calculation of sample
size for this study given that it was decided a priori that
patients with Wagner Grades of 2,3 or 4 would be
recruited into the study. Based on these data, the
expected event rate in the standard care group was
39.29% and 11.54% in the HBOT group and using a
two-sided test for equality.
Using these data, it was estimated that a total of 94
patients were needed for this study (47 patients per
treatment group). However, due to the fact that subjects
might leave the study for a variety of reasons (e.g. loss
to follow-up, non-compliance with treatment, or death),
the sample size was adjusted to accommodate for this.
It was assumed that there was a likely dropout rate of
20%. This assumption would require a total of 118 sub-
jects, or 59 subjects in each treatment group (i.e., 94/(1-
0.20) = 118).
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Two streams of referrals are utilized:
1. Patients referred by primary care physicians undergo
full assessment, including assessment by the participating
vascular surgeon and a foot care specialist to determine
best treatment options for the patient. Once it has been
determined that they are not candidates for surgical/
angioplasty/stenting and they fulfill inclusion criteria
they are asked to participate in the trial.
2. Patients referred by specialists, most commonly vas-
cular and plastic surgeons, usually have already
undergone detailed assessment and their wounds deemed
not amenable by interventional techniques. Previous test
results are forwarded to the participating vascular sur-
geon to examine whether a sufficient level of assessment
has been performed, and whether inclusion/exclusion cri-
teria are met, the patients are then asked to participate in
the study.
Randomisation and Blinding
Patients are randomized using a computerized block
randomization schedule with a multiple block size of
Assessment of Patient Eligibility 
Randomization
Consent and Patient Enrolment 
Baseline Clinical Assessment (within 
14 days prior to initiation of treatment) 
HBOT (active) + 
Standard care for 
6 weeks 
HBOT (placebo) 
+ Standard care 
for 6 weeks 
Follow-up assessments every week 
from week 6 to week 12 from initiation 
of treatment 
Follow-up telephone interviews at 
weeks 30 and 52 
Figure 1 Study Schema.
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ment allocation through an internet-based automated
randomization system. Researchers and patients are
blinded to treatment allocation; the only unblinded indi-
vidual is the technician responsible for controlling the
hyperbaric oxygen chamber.
Interventions
Hyperbaric oxygen therapy
Within 2 weeks of enrolment, each study participant is
placed into the hyperbaric chamber, but only those
patients allocated to active HBOT receive 90 minutes of
oxygen at 2.4 ATA with the patients breathing 100%
oxygen when inside the chamber. Those patients rando-
mized to placebo will be compressed on air to 0.3 ATA
(10 feet) and kept at that level. The patient will remain
in the chamber for the remainder of the placebo treat-
ment breathing normally. At the end of the treatment,
after a short period of enhanced ventilation (to simulate
surfacing) the chamber will be opened. Patients enter
the chambers 5 days per week for approximately 6
weeks for a total of 30 treatments. At the end of the 6
week treatment phase, patients enter a 6-week follow-up
phase.
Dressing changes
Based on the characteristics of the wound, dressings will
be changed as required (at a minimum of 2 dressing
changes per week). Wound care is standardized
throughout the entire study to several different dressing
types (e.g. silver, simple gauze, and alginate, collagen/
oxidized cellullose) dependent on the type of the wound
(e.g. dry, wet, and intermediate). The very wet wounds
receive daily dressing changes as required by standard of
care. Clinical signs of infection are noted and antibiotic
therapy initiated if required and swabs obtained. Referral
for debridement of the wound occurs if necessary.
Data collection
Data to evaluate the efficacy of HBOT are collected at
screening, baseline, and weekly throughout the 6-week
treatment phase, weekly throughout the 6-week follow-
up phase at 30 and 52 weeks. At the end of the 6-week
follow-up phase (i.e. week 12), the patient is sent to the
participating vascular surgeon for an amputation evalua-
tion. If the patient’s wound has not healed, the wound
care physician, in consultation with the vascular surgeon
will then decide if further HBOT or other treatment is
indicated. Once all study data for each patient are
received, the randomization assignment may be revealed.
Data are collected via interview, self administrated ques-
tionnaire, physical and biological measurements. Data
collection instruments and the study timeline are sum-
marized in Table 1. All instruments used have been pre-
viously validated.
Primary Outcome
The primary outcome in this study is freedom from hav-
ing, or meeting the criteria for, a major amputation
(below knee amputation, or metatarsal level) up to 12
weeks after initiation of treatment. The decision to
amputate is made by a vascular surgeon and by meeting
any of the following criteria:
1. Persistent deep infection involving bone and ten-
dons (antibiotics required, hospitalization required,
pathogen involved);
2. Ongoing risk of severe systemic infection related to
the wound;
3. Inability to bear weight on the affected limb;
4. Pain causing significant disability.
Secondary Outcomes
1) Wound healing
Measures of wound healing include difference in wound
measurements (i.e. depth, length, width and extent of
surface area) using: a digital photograph; reduction in
Wagner Classification Score; Bates-Jensen Wound
Assessment score; proportion of wounds closed on or
before 12 weeks; and time to healing (days).
Digital Photographs for Healing Assessment Using a
digital camera with PictZar
® CDM Software, digital
images of the wounds are captured and downloaded to
a computer. Once downloaded to a computer, PictZar
®
CDM Software is used to make various surface measure-
ments on the wound photograph (i.e. depth, length,
width, area, circumference and volume). The software
provides a method of calibrating digital images based on
a calibration strip placed on the skin adjacent to the
wound. Photographs are used for comparison to assess
the degree of ulceration.
Wagner Scale The foot ulcer classification system used in
this study was described and popularized by Wagner [38].
In the Wagner system, the natural history of dysvascular
foot breakdown is divided into six grades ranging from
Grade 0 (preulcer) to Grade 5 (amputation required). The
system is similar to an ordinal scale denoting ranked
order, allowing for nonparametric data analysis. Grade is
determined based on depth of the skin lesion and the pre-
sence or absence of infection and gangrene.
Bates-Jensen Wound Assessment Tool The Bates-Jen-
sen Wound Assessment Tool (Barbara Bates-Jensen
©
2001) [39], is a validated wound assessment tool that
evaluates 13 wound characteristics with each item
scored on a 1-5 scale. A total score is obtained by add-
ing all individual scores and the results are plotted on
the Wound Status Continuum. Higher total scores indi-
cate a more severe wound status.
2) Effectiveness
Maintenance on therapy (discontinuation rates) and sec-
ondary prevention interventions (confounding variables
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control) are collected.
3) Safety
Major morbidity (e.g. infection requiring hospitalization,
acute coronary syndrome, renal failure); wound inter-
ventions during study (debridement, surgery); complica-
tions related to HBOT (seizure, pulmonary syndromes,
vision disturbance, middle ear or sinus problems); and
all cause mortality are recorded on the case report
forms.
4) Healthcare resource utilization
All healthcare resources used by study patients during
the course of the study are documented (e.g. wound
dressing materials, healthcare provider visits; inpatient
hospital admissions; complex continuing care/rehabilita-
tion; drug therapy; mobility assistive devices, etc.).
5) Quality of life
Diabetic foot ulcers are associated with pain, discomfort
and immobility, which could lead to anxiety, depression,
and isolation. As a result, one of the secondary objec-
tives of this study is to measure any changes in HRQL
in the two treatment groups. Three different instru-
ments are utilized: 1) a generic quality of life instrument
- Short-Form 36; 2) a preference-based or utility mea-
sure - EuroQoL 5D (EQ-5D); and 3) a disease-specific
questionnaire - Diabetic Foot Ulcer Scale - Short Form.
Self-assessment will be performed at baseline, 6 weeks,
and 12 weeks in order to monitor the progress or
Table 1 Schedule of study assessments and evaluations
Treatment Phase Follow-up Phase Long-Term
Follow-up
Clinical Assessments, Testing and
Investigations
Screening and
Randomization
Baseline Weeks 1
to 6
End of
Treatment
Weeks 6
to 12
End of
Follow-up
Week
30
Week
52
Suitability for HBOT X
Electrocardiogram O
Pulmonary Function Testing O X
Audiogram O
Chest X-ray O
X-ray of affected limb O X
Nuclear bone scan O
Vascular Exam X O O O O X
History & Physical X
Demographics X
Treatment Details X X
Wound Classifications (Wagner, Bates) X X X X
Wound Measurements X X X
Wound Characteristics X X X
Digital Photograph of wound X X X
Dressing Changes X X X O O
Concomitant Meds X X X
Assess for Infection X X X X
Mobility Status X X X
Adverse Events X X X X X
Outcome Assessment X X X X
Unblinding O O O O O
Laboratories X X X X
Resource Utilization X X X X X
Quality of Life:
SF-36 X X X
EQ-5D X X X X X
DFS-SF X X X
x = required o = optional.
SF-36: Short-Form 36; EQ-5D: EuroQoL 5D; DFS-SF: Diabetic Foot Ulcer Scale - Short Form.
O’Reilly et al. Trials 2011, 12:69
http://www.trialsjournal.com/content/12/1/69
Page 6 of 10decline of the patient through their own interpretation.
Only the EQ-5D will be administered at weeks 30
and 52.
6) Cost effectiveness of HBOT
The final objective of this study is to assign cost values
t ot h eh e a l t h c a r er e s o u r c eu tilization data in order to
determine the incremental cost per amputation avoided
and the incremental cost per quality-adjusted life-year
(QALY) gained associated with the treatments.
Early Discontinuation
If a patient’s wound heals during the treatment phase,
they discontinue the HBOT treatment visits but con-
tinue their weekly visits until week 12. Dressing changes
and prevention care plans are put in place and wound
evaluation visits include the documentation of health-
care resource utilization, quality of life measurements,
and any relevant clinical information.
Alternatively, if amputation criteria are met during the
treatment phase, the outcome is recorded and efforts
made to maintain wound care as per protocol until
amputation procedure can be done or if systemic infec-
tion or ascending infection then immediate referral to
surgery. Healthcare resource utilization is collected
weekly and quality of life is collected for these patients
as per protocol (i.e. 6 and 12 weeks).
If a patient discontinues the assigned treatment due to
inability to tolerate or unwilling to comply with therapy
but is still willing to remain in the study, the patient is
provided standard wound care. Wound evaluation visits
are completed when possible.
If a patient needs to temporarily discontinue treat-
ment due to a medical illness, infection in the wound
where HBOT cannot be continued, or complications of
the wound, this is considered a temporary interruption.
Once the patient has recovered, they may begin a new
HBOT treatment regimen. All patients who have tem-
porarily had their treatment interrupted will be followed
for all regular clinical wound evaluation (Table 1).
Statistical Analysis
Data Analysis
Baseline variables will be evaluated for balance between
the two groups using the Student’s t-test for unpaired data
for the comparison of continuous variables and the Pear-
son’s chi-squared test to compare categorical variables.
For the primary outcome of rate of, or criteria for,
major amputation, the chi-squared test will be used.
Additionally, a relative risk will be estimated for the
major amputation rates in each arm and multivariable
logistic regression analysis of major amputations will be
performed using a number of covariates.
All test instruments for the various secondary out-
comes will be scored according to the recommendations
for the particular tests, with missing values handled in
an appropriate fashion (e.g., prorated sum, average) and
corrections for repeated measures will be applied where
appropriate. Scores for any patients who die prior to the
end of study from causes directly related to their wound
(e.g. sepsis) are considered to have required an amputa-
tion. Patients who die from other causes are eliminated
from further analyses due to lack of follow-up data but
the outcome recorded. When patients are unwilling to
complete a follow-up visit or are lost to follow-up we
will use chi-squared analysis to determine whether there
is imbalance between the treatment groups with respect
to loss of follow-up.
The extent of healing of the ulcers will also be
assessed by measuring the ulcer surface area from the
digital photographs. Since it is a continuous variable,
data will be tested for normality and analyzed as appro-
priate with t-test or non-parametric test if required.
All analyses will be based on the “intention-to-treat”
principle. Per-protocol analyses will also be conducted.
Subgroup Analysis
There are no planned subgroup analyses anticipated.
Only primary and secondary outcome measures will be
analyzed. However, all of the variables which are found
to be important predictors of amputation and adverse
outcomes, will be used for stratifications for post-hoc
analyses.
Health Economic Evaluation
An economic evaluation will be conducted in order to
assess the cost-effectiveness of HBOT plus standard
wound care compared to wound care alone. The analy-
sis will be based upon patient-level outcome and
resource use data from the trial. Two cost-effectiveness
outcomes will be measured: 1) cost per major amputa-
tion avoided; and 2) the cost per QALY gained. Model-
ing techniques will be used to extend the time horizon
beyond the duration of the trial. A third-party payer
perspective (i.e. Ontario Ministry of Health) will be
taken in the evaluation.
Healthcare resource utilization over the duration of
the trial is measured for each patient. A number of dif-
ferent cost components are being considered: HBOT
treatment; follow-up wound care visits; inpatient admis-
sions; general practitioner visits; specialist visits; other
allied healthcare professional visits (e.g. chiropodists,
physiotherapists); and mobility assistive devices (e.g.
wheelchairs, walkers). The cost per HBOT treatment
will be based upon the Judy Dan Wound Care Centre
operating budget. The cost for nurse wound care will be
based upon the average hourly nursing wage in Ontario.
For patients in the active HBOT plus standard care arm,
treatment costs will include both HBOT and wound
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care arm, treatment costs will not include HBOT costs.
Follow-up resource use data will be assessed at the
completion of HBOT treatment (week 6), weeks 12, 30
and 52. Appropriate unit costs will be applied to the
resource use data to estimate follow-up costs for each
patient. Unit costs will be derived from a number of
sources including the Ontario Case Costing Initiative
database and the OHIP Schedule of Benefits.
QALYs for each treatment arm will be based upon
utilities measured over the duration of the trial. Uncer-
tainty of cost-effectiveness results will be estimated
using non-parametric bootstrap techniques and pre-
sented using cost-effectiveness acceptability curves.
Study Organization
Steering Committee
The Steering Committee, which consists of the clinical
and methodological investigators involved with the
study, is responsible for the overall design of the study
and ensures that the execution and management are of
the highest quality. Committee members from the
PATH Research Institute have extensive knowledge in
clinical trial design, data analysis and economic evalua-
tion techniques. The clinical investigators bring exten-
sive knowledge in HBOT wound treatment. The
Steering Committee corresponds on a regular basis to
review the conduct of the study, specifically data related
to: rates of accrual, major protocol deviations and
adverse events.
Programs for Assessment of Technology in Health (PATH)
Research Institute
The PATH Research Institute, based out of St. Joseph’s
Healthcare Hamilton, located in Hamilton, Ontario, is
responsible for the overall coordination of the study,
including protocol development and finalization, design
of case report forms, operations manuals, study materials
and data management (e.g. data collection, validation,
data clarifications). During the study, the PATH Research
Institute is responsible for monitoring the study execu-
tion, particularly with respect to the methodological
aspects, ensuring adherence to the study protocol by the
clinical centre and study personnel involved, preparation
of summary information and reports.
The PATH Research Institutei sr e s p o n s i b l ef o rt h e
final analysis of the dataset and, in consultation with the
investigators, will complete a final report regarding the
use of HBOT to the Ontario Ministry of Health and
Long-term Care. This study is part of a larger program
of research by the PATH Research Institute of conduct-
ing “field evaluations’ with an overall goal to collect
necessary information of new emerging health technolo-
gies in Ontario.
Deviations From Protocol
Patients must meet the inclusion and exclusion criteria
to be enrolled in the study. If, after enrolment, it is
noted that the patient does not meet the inclusion and/
or exclusion criteria, the information is recorded on the
enrolment case report forms. A protocol deviation
report is prepared and kept on file at the clinical centre
as well as on file at the coordinating centre. In addition,
any deviations from the protocol for the remainder of
the study are documented on the case report forms.
Ethical Considerations
This study is being conducted in compliance with the
Canadian Tri-Council Policy Statement: Ethical Conduct
for Research Involving Humans (TCPS), Health Canada
Food and Drug Regulations, and the International Con-
ference on Harmonization (ICH) Guidelines (E6) for
Good Clinical Practice (GCP) and in agreement with the
latest revision of the Declaration of Helsinki, Personal
Health Information Protection Act privacy legislation
and all applicable Canadian laws and regulations, as well
as any local laws and regulations and all applicable
guidelines. This protocol and any amendments have
Research Ethics Board (REB) approval at St. Joseph’s
Healthcare Hamilton (the sponsoring site) (#: 08-3017)
and the University Health Network in Toronto (# 07-
0586-AE). The approval of the REB concerning the con-
duct of the study was made in writing to the investiga-
tor before commencement of the study. An investigator
provides the REB with reports, updates and other infor-
mation periodically, according to the regulatory require-
ments or Institution procedures.
Subject Consent
The informed consent of a patient is obtained from all
potential study participants using the REB-approved
Patient Informed Consent form. The clinical investiga-
tor, or a person designated by the clinical investigator,
and under the clinical investigator’s responsibility,
informs the potential study subject of all pertinent
aspects of the study. All potential participants are
informed of the study in a language and terms they are
able to understand. Subjects are also informed that their
medical care will not be affected should they choose not
to participate. Prior to a subject’s participation in the
study, the Subject Information and Informed Consent
form is signed, name printed and personally dated by
the subject or the subject’s legally acceptable representa-
tive, and by the person who conducted the informed
consent discussion. A copy of the signed and dated Sub-
ject Information and Informed Consent form is provided
to the subject. Documentation that the informed con-
sent was signed and dated prior to any study procedures
being performed is made at the time of the informed
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Page 8 of 10consent and appears in a source document at the clini-
cal centre, such as the subject’s medical record.
Adverse Events
This study is being conducted according to the ICH
Good Clinical Practice Guidelines. Adverse events and
serious adverse events information are documented.
Confidentiality
All records identifying the study subject are kept confi-
dential and, to the extent permitted by the applicable
laws and/or regulations, will not be made publicly avail-
able. The patient’s name appears in the patient consent
form and the contact information sheet which collects
relevant information that the clinical centre will need to
arrange follow-up visits. This information is recorded
l o c a l l ya tt h ec l i n i c a lc e n t r eo n l ya n dw i l ln e v e rb e
received at the coordinating centre and therefore no
patient identification information is recorded in the
study database. At the time of enrolment, each patient
is assigned a unique study identification number. Only
the subject identification number and subject initials are
recorded on the case report forms. If the subject name
appears on any other documents (i.e. source docu-
ments), it must be obliterated before a copy of the docu-
ment is sent to the coordinating centre. Study findings
stored on a computer are protected in accordance with
local data protection laws.
Disscussion
This study has been designed to address some of the
shortcomings of previous research, namely this study
will be the largest and first double-blind randomised
controlled trial to evaluate the efficacy of HBOT for the
prevention of major amputations in diabetic patients
with non-healing ulcers of the lower limb. The study
uses a remote randomization system to protect conceal-
ment of allocation and proposes that the primary
comparative analyses be conducted on an intention-to-
treat basis in accordance with the 2010 CONSORT
statement [40].
Participants are followed up for a 12-month period in
order to capture the impact of HBOT treatment in both
the immediate (i.e. 12 weeks) and longer term. This
two-arm study, with 49 participants per group, should
provide sufficient power to detect a meaningful differ-
ence in amputation. If successful, this intervention may
lead to substantial and important changes in the man-
agement of diabetes patients at risk of amputation due
to non-healing ulcers of the lower limb.
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